07/01/2025
6:40 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form ARS | |
07/01/2025
6:30 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form DEF 14A | |
07/01/2025
6:35 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form DEFA14A | |
06/20/2025
6:20 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2025
1:06 PM | EcoR1 Capital, LLC (Filed by)
Kalaris Therapeutics, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
05/14/2025
7:09 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/16/2025
3:18 PM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/11/2025
4:04 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
PATEL SAMIR CHANDRAKANT (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/11/2025
4:08 PM | Jovan-Embiricos Morana (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/11/2025
4:20 PM | AKKARAJU SRINIVAS (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/11/2025
4:27 PM | Hagen Brett R (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for KLRS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Kalaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
04/11/2025
4:03 PM | Ferrara Napoleone (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/11/2025
3:41 PM | Hallal David (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/04/2025
7:21 AM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
PATTERSON LEONE D (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
04/04/2025
7:12 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/27/2025
6:19 PM | Hagen Brett R (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/26/2025
4:06 PM | AKKARAJU SRINIVAS (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3/A | |
03/25/2025
6:38 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Samsara BioCapital GP, LLC (Reporting)
Samsara BioCapital, L.P. (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/25/2025
6:40 PM | Kalaris Therapeutics, Inc. (Subject)
Kalaris Therapeutics (Subject)
Samsara BioCapital, L.P. (Filed by)
| Form SCHEDULE 13D | |
03/20/2025
3:32 PM | GILEAD SCIENCES, INC. (Filed by)
Kalaris Therapeutics, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
03/18/2025
4:44 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
PATEL SAMIR CHANDRAKANT (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:45 PM | Ferrara Napoleone (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:37 PM | ADAMIS ANTHONY P (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:40 PM | AKKARAJU SRINIVAS (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:41 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Oxtoby Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:43 PM | Feinsod Matthew (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:25 PM | Dybbs Michael (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:27 PM | Ferrara Napoleone (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:30 PM | AKKARAJU SRINIVAS (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:14 PM | ADAMIS ANTHONY P (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:17 PM | Feinsod Matthew (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:20 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Oxtoby Andrew (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:21 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
PATEL SAMIR CHANDRAKANT (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:04 PM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/12/2025
3:18 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/07/2025
6:30 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/24/2025
10:51 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/24/2025
10:55 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/24/2025
10:56 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/14/2025
12:17 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
| Form SCHEDULE 13G/A | |
02/10/2025
11:15 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form EFFECT | |
Which Gold Miner Trades at 30% of NAV? The One Buffett Wants (Ad) Some of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents.
With gold at record highs and Bridgewater now buying in, one analyst believes Buffett’s next move could hit by August 15th. He’s identified the gold miner that fits Buffett’s profile — plus four smaller plays with even more upside. Get the name of Buffett’s likely gold target here |
02/10/2025
3:19 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 424B3 | |
01/24/2025
1:51 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/24/2025
1:55 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/24/2025
2:03 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025
3:39 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/15/2025
3:41 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
01/13/2025
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Sinha Vikas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Hagen Brett R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/10/2025
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2025
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2025
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2025
6:44 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
01/10/2025
6:42 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/20/2024
3:21 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/20/2024
3:23 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
12/11/2024
4:07 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
5:37 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form S-4
Registration statement under Securities Act of 1933 | |
12/06/2024
8:50 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
12/06/2024
6:23 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form DEF 14A | |
11/20/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Brainard Diana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/20/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/20/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Sinha Vikas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/20/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Hagen Brett R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/19/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/19/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/19/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/19/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/08/2024
3:05 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/08/2024
3:06 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/08/2024
3:09 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/08/2024
3:10 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/08/2024
7:26 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/08/2024
7:33 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/05/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/05/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/05/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/05/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Hagen Brett R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Sinha Vikas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Brainard Diana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/04/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Hagen Brett R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
The End of Elon Musk…? (Ad) The End of Elon Musk? Don't make him laugh.
Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again.
And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again.
According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. Click here to see why the "End of Elon" crowd is about to be wrong again. |
10/04/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Brainard Diana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/04/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/04/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Sinha Vikas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/22/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Brainard Diana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
10:14 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
